Sorafenib-induced multiple eruptive keratoacanthomas;Kératoacanthomes multiples éruptifs induits par le sorafénib

Annales de Dermatologie et de Venereologie

Volumn 136, Issue 12, 2009, Pages 894-897

  Jantzem, H ^a   Dupre Goetghebeur, D ^b   Spindler, P ^c   Merrer, J ^d  

^a SERVICE DE RHUMATOLOGIE   (France)

^b CHU MORVAN   (France)

^c BREST UNIVERSITY HOSPITAL   (France)

^d CLINIQUE PASTEUR   (France)

Author keywords

Eruptive keratoacanthomas; Sorafenib

Indexed keywords

ENALAPRIL; FLUOROURACIL; PIRETANIDE; SORAFENIB; ZOPICLONE;

ADULT; ANTIANGIOGENIC THERAPY; ARTICLE; CASE REPORT; CRYOTHERAPY; EVENING DOSAGE; HUMAN; HYPERTENSION; KERATOACANTHOMA; KERATOSIS; KIDNEY METASTASIS; MALE; MORNING DOSAGE; SKIN BIOPSY; SKIN DEFECT; TREATMENT DURATION;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KERATOACANTHOMA; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PYRIDINES; SKIN DISEASES; SUNLIGHT;

EID: 73349103124     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.annder.2009.09.010     Document Type: Article

References (26)

1. D.A. Murphy, S. Makonnen, W. Lassoued, M.D. Feldman, C. Carter, and W.M. Lee Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006) Am J Pathol 169 2006 1875 1885 (Pubitemid 351182016)
2. S. Wilhelm, C. Carter, M. Lynch, T. Lowinger, J. Dumas, and R.A. Smith Discovery and development of sorafenib: a multikinase inhibitor for treating cancer Nat Rev Drug Discov 5 2006 835 844 (Pubitemid 44480537)
3. H.H. Kong, E.W. Cowen, N.S. Azad, W. Dahut, M. Gutierrez, and M.L. Turner Keratoacanthomas associated with sorafenib therapy J Am Acad Dermatol 56 2007 171 172
4. C. Robert, J.C. Soria, A. Spatz, A. Le Cesne, D. Malka, and P. Pautier Cutaneous side-effects of kinase inhibitors and blocking antibodies Lancet Oncol 6 2005 491 500 (Pubitemid 40903630)
5. C. Robert Effets secondaires cutanés des molécules anti-angiogéniques Bull Cancer 94 2007 S260 S264 (Pubitemid 47401369)
6. M. Deslandres, V. Sibaud, C. Chevreau, and J.P. Delord Effets secondaires cutanés des nouvelles molécules anticancéreuses : focus sur les molécules ciblant les récepteurs tyrosine kinase et le récepteur à l'EGF Ann Dermatol Venereol 1 2008 16 24 (Pubitemid 351620943)
7. J. Autier, C. Mateus, J. Wechsler, A. Spatz, and C. Robert Effets secondaires cutanés du sorafénib et du sunitinib Ann Dermatol Venereol 135 2008 148 153 (Pubitemid 351625321)
8. N. Heidary, H. Naik, and S. Burgin Chemotherapeutic agents and the skin: An update J Am Acad Dermatol 58 2008 545 570
9. B. Bégaud, J.C. Evreux, J. Jouglard, and G. Lagier Imputation des effets inattendus ou toxiques des médicaments. Actualisation de la méthode utilisée en France Therapie 40 1985 111 118
10. B. Cribier Vous avez dit kératoacanthome ? Dites plutôt « carcinome spinocellulaire à type de kératoacanthome » Ann Dermatol Venereol 135 2008 541 546
11. R.A. Schwartz Keratoacanthomas: a clinicopathologic enigma Derm Surg 30 2004 326 333
12. D.H. Chu, E.K. Hale, and P. Robins Generalized eruptive keratoacanthomas Dermatol Online J 9 2003 36
13. S.A. Wee Multiple eruptive keratoacanthomas, de novo Dermatol Online J 10 2004 19
14. M.W. Dessoukey, M.F. Omar, and H. Abdel-Dayem Eruptive keratoacanthomas associated with immunosuppressive therapy in a patient with systemic lupus erythematosus J Am Acad Dermatol 37 1997 478 480 (Pubitemid 27430647)
15. C. Dangoisse, K. Meyvisch, and M. Ledoux Multiple eruptive keratoacanthoma and immunity disorders Dermatology 186 1993 313 316 (Pubitemid 23154562)
16. T.Y. Chuang, L.A. Heinrich, M.D. Schultz, G.T. Reizner, R.C. Kumm, and D.J. Cripps PUVA and skin cancer. A historical cohort study on 492 patients J Am Acad Dermatol 26 1992 173 177
17. B. Guillot, H. Fesneau, G. Mourad, C. Mion, and J.J. Guilhou Kératoacanthomes multiples sous cyclosporine Presse Med 19 1990 1286
18. A.C. Esser, A. Abril, S. Fayne, and J.A. Doyle Acute development of multiple keratoacanthomas and squamous cell carcinomas after treatment with infliximab J Am Acad Dermatol 50 2004 S75 S77
19. S. D'Addario, and P.R. Carrington Multiple keratoacanthomas as an untoward response to imiquimod therapy for actinic keratoses Acta Derm Venereol 86 2006 366 367 (Pubitemid 44133392)
20. K. Kobayashi, D.S. Pezen, N.J. Vogelzang, M. Medenica, L. Janisch, and M. Ratain Keratoacanthomas and skin neoplasms associated with suramin therapy Arch Dermatol 132 1996 96 98 (Pubitemid 26024825)
21. J. Autier, B. Escudier, J. Wechsler, A. Spatz, and C. Robert Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor Arch Dermatol 144 2008 886 892 (Pubitemid 352039741)
22. J.P. Janik, and R.H. Bang Traumatic keratoacanthoma arising in a 15-year-old boy following a motor vehicle accident Pediatr Dermatol 23 2006 448 450
23. B.I. Rini Sorafenib Expert Opin Pharmacother 7 2006 453 461 (Pubitemid 43379611)
24. W. Zhao, Y.H. Gu, R. Song, B.Q. Qu, and Q. Xu Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation Leukemia 22 2008 1226 1233 (Pubitemid 351833791)
25. H.H. Kong, V. Sibaud, M.L. Chanco Turner, T. Fojo, T.J. Hornyak, and C. Chevreau Sorafenib-induced eruptive melanocytic lesions Arch Dermatol 144 2008 820 822 (Pubitemid 351846901)
26. Bennani-Lahlou, C. Mateus, B. Escudier, C. Massard, J.C. Soria, A. Spatz, et al. Nævus éruptifs sous sorafénib Ann Dermatol Venereol 135 2008 672 674